Market Overview

Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Related NAVB
Navidea Joins Essex Woodland's Rheumco, Will Develop Radiopharmaceuticals To Detect And Treat Arthritic Diseases
UPDATE: Navidea Biopharma Announces Positive Lymphoseek Injection Results

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

Posted-In: News


Related Articles (NAVB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters